Naphthamide is a common structural framework with diverse
pharmacological
activities. Ten novel 2-naphthamide derivatives have been designed,
synthesized, and evaluated for their
in vitro
antibacterial,
antifungal, and anticancer activities. The title compounds were synthesized
from dimethoxybenzaldehyde derivatives through a four-step microwave-assisted
synthesis process. The structures were confirmed by
1
H
NMR,
13
C NMR, and MS spectra. Compound
8b
showed
good antibacterial activity against
Escherichia coli
,
Streptococcus faecalis
,
Salmonella enterica
, MSSA, and MRSA with MIC values
of 16, 16, 16, 8, and 16 μg/mL, respectively, compared to ciprofloxacin
(MIC = 8–16 μg/mL). Compounds
5b
(IC
50
= 3.59–8.38 μM) and
8b
(IC
50
= 2.97–7.12 μM) exhibited good cytotoxic activity
against C26, HepG2, and MCF7 cancer cell lines as compared to paclitaxel
(IC
50
= 2.85–5.75 μM). Moreover, compounds
5b
and
8b
exhibited better anticancer activity
than PTX against the C26 cell line. In particular, compound
8b
showed potent
in vitro
VEGFR-2 inhibitory
activity with the IC
50
value of 0.384 μM compared
with sorafenib (IC
50
= 0.069 μM). Therefore, compound
8b
is the most potent compound for anticancer activity as
indicated by
in vitro
cell line inhibition,
in silico
ADMET, molecular docking, and
in vitro
VEGFR-2 inhibition studies.